OCCLUFIT: A NEW PORTFOLIO COMPANY OF THE UZH LIFE SCIENCES FUND
18 June 2019
The UZH Life Sciences Fund is proud to welcome Occlufit as a new portfolio company.
Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects. Developed under the expert guidance of Prof. Francesco Maisano, Dr. Monica Tocchi (CEO), Dr. Andrea Guidotti (COO) and Dr. Amir Gross (CFO) , Occlufit will treat patients with a minimally invasive percutaneous approach to prevent heart failure and stroke.
This is the fifth investment of the LSF in early spin-offs of the University of Zurich after EraCal Therapeutics (Josua Jordi), ImmunOs Therapeutics AG (Osiris Marroquin Belaunzaran), Anaveon (Onur Boyman) and Cutiss AG (Daniela Marino). The UZH Life Science Fund is a joint initiative of the University of Zurich (Prof. Michael Hengartner, Prof. Christoph Hock) and the Novartis Venture Fund (Anja König, Beat Steffen). More on the UZH Life Science Fund.